丽珠医药(01513.HK)中期归母净利润7.39亿元同比增长16.67%
格隆汇8月16日丨丽珠医药(01513.HK)公告,截至2019年6月30日止6个月,公司收入49.39亿元人民币,同比增长8.2%;归属于公司股东的净利润7.39亿元,同比增长16.67%;归属于公司股东的扣除非经常性损益的净利润6.59亿元,同比增长15.32%;每股收益1.03元。
报告期内,该集团制剂药业务实现销售收入人民币3,330.42百万元,占该集团报告期实现营业收入的67.43%,其中化学制剂人民币2,620.97百万元,较上年同比增长22.19%;中药制剂人民币709.45百万元,较上年同比下降17.68%。化学制剂收入占比持续增大。
报告期内,该集团原料药及中间体业务实现销售收入约人民币1,219.00百万元,占该集团报告期实现营业收入的24.68%,较上年同比增长1.64%,而营业利润率较上年同比增长7.18%,盈利能力继续增强。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.